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Regarding "Infected thrombophlebitis of the right 
internal jugular vein" 
To the Editors: 
Catheter-related septic central venous thrombosis can 
be an elusive diagnosis. The case described by Terada et al. 
(1996;24:1066-7) is convincing, but I must differ with the 
espoused surgical treatment. 
When I reviewed the literature in presenting a series of 
four patients, 1 it was clear that the majority of cases had 
been successfully treated with a prolonged course of intra- 
venous antibiotics and anticoagulation with heparin. Over 
the last decade, I have continued to accrue xperience with 
new cases at a rate of one per year, and in no instance has 
excision of a central vein proved necessary. As opposed to 
the management of peripheral septic phlebitis, for which 
excision is clearly the treatment of choice, sepsis in central 
veins seems to take a different course. The role ofheparin is
speculative, but it may act to halt incorporation ofbacteria 
into fresh, unorganized thrombus. Thrombectomy to de- 
bulk the septic lot has been reported 2 but does not appear 
to have an advantage over antibiotics and heparin alone. 
In the literature, there is no consensus on the duration 
ofheparin administration (I have used 1 to 2 weeks, stop- 
ping after the bacteremia has clearly ceased), on the utility 
of warfarin, and on the length of administration f antibi- 
otics (analogous to the treatment of endocarditis, I have 
advocated 6 weeks). In the otolaryngology literature, the 
analogous clinical problem is the Lemierre syndrome, sep- 
tic jugular thrombosis originating in an oropharyngeal 
infection, for which antibiotics are the primary treatment. 3 
In the neurology/neurosurgery literature, septic dural si- 
nus thrombosis also primarily treated without excision. 4 
In all of these syndromes, urgery should be reserved for 
persistent bacteremia despite anticoagulation a d intrave- 
nous antibiotics and where there is no evidence that endo- 
carditis is present, s 
Jeffrey L. Kaufman, MD 
Division of Vascular Surgery 
Baystate Medical Center 
759 Chestnut St. 
Springfield, MA 01199 
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24/41/80992 
Reply 
To the Editors: 
We appreciate he opportunity orespond to Dr. Kauf- 
man's letter. 
Our case was a rare situation. First, bacteremia devel- 
oped 4 weeks after the catheter was removed. The throm- 
bus was already organized. The organized thrombus was 
infected and contained purulent pus. Second, methicillin- 
resistant Staphylococcus aureus bacteremia was not con- 
trolled by vancomycin travenously. In a report by Raad et 
al., 1 of the 12 patients who had septic thrombosis caused 
by S. aureus, deep-seated infections (septic emboli, endo- 
carditis, meningitis, and abscess) developed infive patients. 
Heparin may be important in halting the extension of 
septic thrombus and the incorporation of bacteria into 
fresh, unorganized thrombus, as Dr. Kaufman mentions. 
We have no supporting data; however, we do not believe 
that intravenous vancomycin could penetrate an organized 
and infected thrombus, as in our case. 
We agree with Kaufman et al. 2 that catheter removal, 
anticoagulation, and a long course of appropriate intrave- 
nous antibiotics are the initial therapy in patients who have 
fresh septic entral venous thrombosis. We greatly appreci- 
ate Dr. Kaufman's commenting on our article. 
Yasushi Terada, MD 
Department ofCardiovascular Surgery 
Institute of Clinical Medicine 
University of Tsukuba 
Tsukuba-shi 
Ibaraki-ken 305, Japan 
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Prospective randomized trials of carotid 
endarterectomy with primary closure and patch 
reconstruction: The problem is power 
To the Editors: 
In a recent report hat compared primary closure with 
three patch reconstruction materials (AbuRahma et al., J 
Vasc Surg 1996;24:998-1007), the authors state in the 
methods ection that the statistical tests may be underpow- 
ered. No further consideration is given to the possible 
effects of low statistical power in discussing the results or 
making recommendations. With the exception of early 
residual or restenosis -50%, many of the multiple compar- 
isons of primary closure with patching flirt with the usual 
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"statistically significant" 0.05 p value. Although the au- 
thors use the Bonferroni correction for three comparisons 
(0.050 becomes 0.0167), p values in the 0.2 to 0.02 range 
must be taken seriously. The use of a one-tailed Fisher 
exact test may be inexact in that the proper test may be 
two-tailed. This can increase p values up to twice the 
one-tailed value. This point not withstanding, the real 
problem with interpreting the results of this excellent 
study, as it is with those of the five previously published 
prospective randomized trials of primary closure versus 
patch reconstruction, l~sis the power of the statistical tests 
used. Power quantifies the probability of detecting a real 
difference of a given size in two methods or treatments. 
Power is the proportion of the test statistic (p) that falls 
below a certain chance of a type I error (false negative), 
usually p < 0.05, given that a method or treatment has a 
real effect. Put another way, the power of a test tells the 
likelihood that the hypothesis of no effect (or difference in 
outcome of two treatments) will be rejected when the 
treatment actually has an effect (i.e., a true positive). For 
example, for a cutoff of 0.05 for statistical significance, 
power is the likelihood that if the study were repeated with 
the same sample size in each arm the new p value would be 
less than 0.05. The sample size plays a major role in 
determining power. In the study by Dr. AbuRahma et al., 
the results of primary closure versus various patch recon- 
structions for perioperative stroke gave p values from 0.015 
to 0.06, and for early internal carotid occlusion 0.03 to 
0.22. The powers computed from the data in the contin- 
gency tables range from 0.29 to 0.55 for a cutoff value of 
0.05. This means that if the study were repeated with the 
same sample sizes, the chance of obtaining a p value less 
0.05 ranges from 29% to 55%, depending on the subset 
being tested. This illustration is typical (actually on the 
high side) of power values computed for stroke, occlusion, 
and early restenosis for the five previously published pro- 
spective randomized trials, l s  The sample sizes are simply 
too small to detect 3% to 6% differences with adequate 
power. These five studies have mixed results in terms of 
whether or not patching affects early outcomes of carotid 
endarterectomy, 
Analysis of the pooled raw data from these six studies 
for the three endpoints--perioperative int rnal carotid oc- 
clusion, 30-day stroke, and early >50% residual stenosis or 
restenosis--gives some sobering results. The incidence of 
occlusion is 20 of 462 (4.3%) for primary closure and 5 of 
641 (0.8%) for patch reconstruction (p < 0.001 by ×2; 
power, 0.99). The chance of a type II statistical error,/3 = 
1 -power,  is 0.01 for occlusion. The incidence of stroke is 
18 of 462 (3.9%) for primary closure and 8 of 641 (1.2%) 
for patch reconstruction (p = 0.008; power, 0.83; /3 = 
0.17). Given the many causes ofperioperative stroke, this 
result indicates that the type of carotid endarterectomy 
reconstruction is a major, if not the major, independent 
variable. The incidence of ->50% stenosis is 33 of 448 
(7.4%) for primary closure and 13 of 630 (2.1%) for patch 
reconstruction (p < 0.001; power, 0.99; [3 = 0.01). The 
results of these pooled data are compelling, even though 
when taken individually only three of the six studies con- 
cluded that patch reconstruction was superior to primary 
closure. Taken pooled, the probability of a false positive 
result is very low and a true positive result very high. 
Given these pooled results, it may be difficult for ade- 
quately informed patients to agree in the future to random- 
izing their operation between primary closure and patch 
reconstruction. The threefold ifference between the 3.9% 
(95% confidence l vel, 2.1% to 5.7%) probability ofa peri- 
operative stroke with primary closure versus 1.2% (95% 
confidence l vel, 0.3% to 2.1%) is enough to deter obliga- 
tory primary closure. Few would accept a flip of the coin 
that gives a 50-50 chance of a three-times-higher chance of 
a perioperative stroke. Future prospective randomized tri- 
als of primary closure versus patch reconstruction may be 
difficult o accomplish. Are they really necessary? 
Joseph P. Archie, Jr., MD 
Carolina Cardiovascular Surgical Associates 
3020 New Bern Avenue, Suite 560 
Raleigh, NC 27610 
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Reply 
To the Editors: 
We appreciate the comments and critique offered by 
Dr. Joseph P. Archie, Jr., and we would like to offer the 
following response. 
We agree with Dr. Archie that statistical tests that do 
not reach the traditional threshold of statistical significance 
should "be taken seriously." The study was powered based 
on anticipated event rates (i.e., restenosis) in a long-term 
follow-up trial. The analysis presented in our article repre- 
sents the 30-day morbidity/mortality analysis of the study. 
Because the duration of follow-up was less than that of the 
final study follow-up and because the endpoints evaluated 
in the 30-day morbidity/mortality analyses were not the 
